<DOC>
	<DOC>NCT00527423</DOC>
	<brief_summary>Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular degeneration.</brief_summary>
	<brief_title>Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD</brief_title>
	<detailed_description>Randomized, Single-Masked Phase II study for subjects previously enrolled in Phase I and II studies for wet age-related macular degeneration with VEGF Trap-Eye intravitreal injection as treatment.Long term (3 years) treatment is intended to measure safety and tolerability, as well as frequency of re-treatment and the effect of VEGF Trap-Eye on best corrected visual acuity (BCVA).</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Prior participation in VEGF TrapEye Phase I and II studies Any ocular or systemic adverse events that would preclude participation Presence of any condition that would jeopardize subject's participation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>VEGF Trap-Eye</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
</DOC>